BeiGene, Ltd. (BGNE)

業務介紹

北京金山生物科技有限公司是一家專注於發現、開發、製造和商業化各種全球醫藥的生物技術公司。其產品包括:

BRUKINSA用於治療復發/難治性(R/R)套細胞淋巴瘤;
Tislelizumab用於治療R/R典型霍奇金淋巴瘤;
REVLIMID用於治療多發性骨髓瘤;
VIDAZA用於治療骨髓增生異常綜合徵、慢性骨髓單核細胞白血病和急性髓性白血病;
XGEVA用於治療骨巨細胞瘤;
BLINCYTO用於治療急性淋巴細胞白血病;
KYPROLIS用於治療R/R多發性骨髓瘤;
SYLVANT用於治療特發性多中心卡斯特曼病;
QARZIBA用於治療神經母細胞瘤;
Pamiparib用於治療各種實體瘤;
Pobevcy用於治療轉移性結直腸癌、肝癌和非小細胞肺癌(NSCLC)。

該公司的臨床階段藥物候選物包括:

Zanubrutinib,一種BTK抑制劑,用於治療淋巴瘤;
Tislelizumab,一種抗PD-1抗體,用於治療實體瘤和血液惡性腫瘤;
Lifirafenib和BGB-3245,用於治療黑色素瘤、NSCLC和子宮內膜癌;
Sitravatinib,一種多激酶抑制劑,用於治療NSCLC、黑色素瘤和其他實體瘤;
BGB-A333,一種PD-L1抑制劑,用於治療各種實體瘤;
Ociperlimab,一種TIGIT抑制劑,用於治療各種實體瘤;
BGB-11417,一種小分子Bcl-2抑制劑,用於治療成熟B細胞惡性腫瘤;
BGB-A445,一種OX40激動抗體,用於治療實體瘤;
Zanidatamab,一種雙特異性HER2抑制劑,用於治療乳腺癌和胃癌;
BGB-A425,一種T細胞免疫球蛋白和黏蛋白結構域3抑制劑,用於治療各種實體瘤;
BGB-15025,一種HPK1小分子抑制劑。

該公司與Shoreline Biosciences, Inc.、Amgen Inc.、Novartis AG和Bristol Myers Squibb公司有戰略合作關係。北京金山生物科技有限公司成立於2010年,總部位於馬薩諸塞州劍橋。



BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.beigene.com